Health

Expert opinions: Will MFN reduce US drug prices? Robots in maternity care. What drives company decisions on new medicine launches and UK investment? Incorporating dynamic pricing into HEOR models (dynamicpv) Tale of 2 value sets. How to handle the lows? Honesty. Integrity in journalism: Giannis edition.

In a recent report, the Association of the British Pharmaceutical Industry (ABPI) examines the UK’s “translational readiness gap”—the persistent failure to move cutting-edge laboratory models into the actual creation of medicines to treat patients. The Attrition Problem and the Translational Gap Modern drug development is a high risk endeavor. Approximately 90% of drug candidates that…

That is the question asked by a 2022 NBER working paper by Pierre Dubois, Ashvin Gandhi and Shoshana Vasserman. Methodology: Demand Side Model The authors used IQVIA data on revenues and quantities of drugs sold to hospitals from 2002 to 2013 across US, Canada, France, Germany, Italy, Spain and UK markets. The authors define a…

Simple: get people vaccinated. Dr. Oz agrees. The New York Times reports: Dr. Oz, the Centers for Medicare and Medicaid Services director, told CNN on Sunday that there was a simple solution to the raging measles outbreak in South Carolina, which has infected more than 900 people and become the largest U.S. outbreak in recent…

That is the title of a paper I published today in Journal of Market Access & Health Policy with co-authors by Karim EI-Kersh, Nadine Zawadzki, Catelyn Coyle, Shurui Zhang, Dhruv Dalal, Anna Watzker, and Dominik Lautsch. The abstract is below: Pulmonary arterial hypertension (PAH) and cancer share high mortality and complex prognoses. Due to PAH’s…